Integra LifeSciences (NASDAQ:IART) Rating Increased to Hold at Wells Fargo & Company

Wells Fargo & Company upgraded shares of Integra LifeSciences (NASDAQ:IART) to a hold rating in a research note published on Wednesday,Zacks.com reports.

Several other equities analysts have also issued reports on the company. Citigroup lowered their price target on Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a research note on Wednesday, March 11th. Wall Street Zen downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Integra LifeSciences has a consensus rating of “Reduce” and a consensus target price of $14.40.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $8.90 on Wednesday. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. Integra LifeSciences has a one year low of $8.76 and a one year high of $23.16. The company has a fifty day moving average price of $11.18 and a 200 day moving average price of $12.75. The stock has a market cap of $693.67 million, a P/E ratio of -1.32 and a beta of 1.02.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.04. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The company had revenue of $434.93 million for the quarter, compared to analyst estimates of $429.62 million. During the same period last year, the business posted $0.97 EPS. The business’s quarterly revenue was down 1.7% on a year-over-year basis. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in IART. Global Retirement Partners LLC acquired a new stake in Integra LifeSciences during the fourth quarter valued at approximately $25,000. GAMMA Investing LLC raised its holdings in shares of Integra LifeSciences by 55.3% in the 3rd quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock worth $37,000 after buying an additional 913 shares in the last quarter. Osaic Holdings Inc. lifted its position in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after buying an additional 1,104 shares during the period. EMC Capital Management bought a new position in shares of Integra LifeSciences during the 2nd quarter worth approximately $75,000. Finally, Tower Research Capital LLC TRC boosted its stake in Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after buying an additional 6,814 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.